TESLASCAN Drug Patent Profile
✉ Email this page to a colleague
When do Teslascan patents expire, and when can generic versions of Teslascan launch?
Teslascan is a drug marketed by Ic Targets and is included in one NDA.
The generic ingredient in TESLASCAN is mangafodipir trisodium. Additional details are available on the mangafodipir trisodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TESLASCAN?
- What are the global sales for TESLASCAN?
- What is Average Wholesale Price for TESLASCAN?
Summary for TESLASCAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 22 |
| Clinical Trials: | 1 |
| DailyMed Link: | TESLASCAN at DailyMed |
Recent Clinical Trials for TESLASCAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| PledPharma AB | Phase 2 |
| Egetis Therapeutics | Phase 2 |
US Patents and Regulatory Information for TESLASCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ic Targets | TESLASCAN | mangafodipir trisodium | INJECTABLE;INJECTION | 020652-001 | Nov 26, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TESLASCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ic Targets | TESLASCAN | mangafodipir trisodium | INJECTABLE;INJECTION | 020652-001 | Nov 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Ic Targets | TESLASCAN | mangafodipir trisodium | INJECTABLE;INJECTION | 020652-001 | Nov 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Ic Targets | TESLASCAN | mangafodipir trisodium | INJECTABLE;INJECTION | 020652-001 | Nov 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Ic Targets | TESLASCAN | mangafodipir trisodium | INJECTABLE;INJECTION | 020652-001 | Nov 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Ic Targets | TESLASCAN | mangafodipir trisodium | INJECTABLE;INJECTION | 020652-001 | Nov 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TESLASCAN
See the table below for patents covering TESLASCAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Norway | 840223 | ⤷ Sign Up | |
| Austria | 118010 | ⤷ Sign Up | |
| Australia | 607456 | ⤷ Sign Up | |
| Finland | 88164 | ⤷ Sign Up | |
| United Kingdom | 2169598 | PHYSIOLOGICALLY TOLERABLE METAL COMPLEX SALTS FOR USE IN NMR DIAGNOSIS | ⤷ Sign Up |
| Finland | 79026 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TESLASCAN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0290047 | 97C0108 | Belgium | ⤷ Sign Up | PRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522 |
| 0290047 | C00290047/01 | Switzerland | ⤷ Sign Up | FORMER REPRESENTANTIVE: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAELTE, CH |
| 0290047 | SPC/GB97/078 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522 |
| 0071564 | SPC/GB93/060 | United Kingdom | ⤷ Sign Up | |
| 0290047 | 67/1997 | Austria | ⤷ Sign Up | PRODUCT NAME: MANGAFODIPIR; REGISTRATION NO/DATE: SG(97)D/3940 19970522 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
